AVITAR AIMS TO INCREASE ITS SHARE IN $1.5B DIAGNOSTIC MARKET

November 28, 2007

Canton, MA – (BUSINESS WIRE)—Avitar Inc. ("AVTI"), manufacturers of nationally branded oral fluid testing diagnostic devices and customized polyurethane applications used in wound dressings, announced today that, because of a recent GAO study of the Department of Transportation urine-based testing procedures and their high rate of failures, the patented Avitar ORALscreen® technology will quickly gain favor. Drug abuse remains a major problem in the transportation sector, as well as construction, manufacturing, hospitality, and retail, due to the limitations associated with urine-based drug testing. Peter Phildius, Avitar’s Chairman and CEO, discussed the GAO study. "We believe that the door is now open wide for us to capture a large segment of the estimated $1.5B drug testing market. We are already selling several cross-sector industry leaders, (Best Buy, Delmonte, Hilton, Sheraton and ADM), as well as small- to mid-sized companies that are receiving multiple benefits, such as lower employee turnover, higher quality workforce, and reductions of up to 50% in their accident rates. There is no competitive product to our ORALscreen® instant on-site testing device which detect prescription pain relievers such as Oxycontin® and Percoset®, as well as other commonly abused substances in 15 minutes or less." Being relatively unknown for the past six years, the Company looks to 2008 as a banner year for rapid expansion into all segments of the drug testing market. The Company has hired a PR firm to begin "telling our story", elevating investor awareness and shareholder value. About Avitar, Inc. Avitar Inc. develops, manufactures and markets innovative proprietary products. Markets include fluid diagnostics, disease and clinical testing, and customized applications for wound dressings. Principal products include ORALscreen®, (the first non-invasive, rapid, onsite oral fluid test for drugs-of abuse), and Hydrasorb®, (an absorbent topical dressing for moderate to heavy exudating wounds). Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at https://avitarinc.com. Avitar Inc. is a fully reporting company whose stock trades on the OTCBB under the symbol "AVTI.OB". For information, contact Investor Relations - Peter Cholakis, VP – Marketing. Forward-Looking Statements This release contains forward-looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company’s actual results could differ materially from those anticipated in such forward-looking statements.